Skip to main content

The 17th World Congress on Targeting Mitochondria 2026

October 21st to 23rd, Berlin

Kevin Slawin, MD, Founder and CEO, Eos SENOLYTIX

Dr. Slawin’s address, “Building on the Foundation of Four:  Advancing Mitochondrial‑Targeted Geropeptide Medicine” will directly follow Dr. Hazel H. Szeto’s historic keynote address, From Mitochondrial Discovery to Approved Therapy: Lessons for the Future of Medicine
that is scheduled to open the conference.

For more about the congress:

WMS 2026 Agenda

WMS Congress Archives

WMS Newsletter